Navigation Links
Small Doses Of Radiation Can Help Certain Lung Cancer Patients

A new study published in the in the March 1, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society says that many patients with apparently// incurable non-small cell lung cancer (NSCLC) survived for up to five years after being given small doses of radiation therapy meant to ease the symptoms of the cancer.

The study says that this group of patients appears to have a different variety of lung cancer that can be sufficiently cured with small doses of radiation. This explains why many people attribute miraculous cures to faith healing and other unconventional methods. Michael Mac Manus, M.D., a radiation oncologist at the Peter MacCallum Cancer Center in Melbourne, Australia, and colleagues monitored the progress of 2337 patients, whose cancer was ruled incurable. All these patients had received small doses of radiation meant to be "palliative." It was found that 1.1 percent of these patients survived for five years or more with 18 patients actually achieving a complete cure. "Our data show that close to 1 percent of patients with NSCLC have prolonged survival with doses of palliative RT that would not normally be considered sufficient for long term disease control," the researchers concluded. They added that in future studies should document patient characteristics since "prospective identification of such patients could potentially profoundly influence treatment." NSCLC happens to be the most common form of lung cancer with a low survival rate of only 40 percent up to five years. However, if diagnosed early, this rate can reach up to 60 percent.

Original Article: "Unexpected Long-Term Survival after Low-Dose Palliative Radiotherapy for Nonsmall Cell Lung Cancer," Michael P. Mac Manus, Jane P. Matthews, Morikatsu Wada, Andrew Wirth, Valentina Worotniuk, CANCER; Published Online: January 23, 2006 (DOI: 10.1002/cncr.21704 ); Print Issue Date: March 1, 2006.

Contact: Amy Molnar
amolnar@wiley.com
John Wiley
'"/>




Page: 1 2

Related medicine news :

1. Smallpox as Biological Weapons?
2. Is Smallpox Threat Real ?
3. Smallpox Vaccine May Help Fight Cervical Cancer
4. Smallpox Would Spread Rapidly
5. Drug Firm Offers to Donate Smallpox Vaccine
6. Small aneurysms best left untouched
7. Small lumps in breast if not treated may cause long-term harm
8. Third generation Small pox vaccine from Cell-culture
9. CT Scans Said to Accurately Detect Small Cancers
10. Brain of Cocaine Addicts Smaller In Size
11. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
Post Your Comments:
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
Breaking Medicine News(10 mins):Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2
...tudy of its kind, a Mexican health care program cr... crippling health care costs among poorer househol...Popular program, and arise from an evaluation cond... establish that the program achieved its main goal...
...th in Long-Term Survivors of Hereditary Retinoblas...stoma are at an increased risk of death due to a s... Retinoblastoma is a very rare cancer of the eye ...he risk of death due to these subsequent cancers i...
...te have found that the growth factor known as TGF-... in the retina and that blocking it can cause reti...April 2 issue of PLoS ONE , may have an important...hey add to our understanding of the molecules that...
...ement of these growths needs to be tailored , ...e cancer cell can lead to multiple, anatomically d...e types of tumors usually look similar, but, until...dy by a team at the Indiana University School of M...
...e interventions in future, study finds , ,...ve treatment in the first two years after a diagno...ove patient survival, a new study finds. , Researc...ceived the most intensive treatment was $7,131 com...
...nd should be urged, expert says, , , TUESD...of moderate exercise will not harm people with hea... a new study has found. , That admittedly tepid co...e. , Some were started on a 36-session training pr...
Other Medicine News:Health News:Mexican health care program successful at reducing crippling health care costs 2Health News:Mexican health care program successful at reducing crippling health care costs 3Health News:Also in the April 7 JNCI 2Health News:Also in the April 7 JNCI 3Health News:Also in the April 7 JNCI 4Health News:Growth factor TGF-B helps maintain health of retinal blood vessels 2Health News:Single Cell May Produce Multiple Lung Cancer Tumors 2Health News:Intensive Early Treatment Doesn't Help Bladder Cancer Survival 2Health News:Exercise Might Benefit Some With Heart Failure 2Health News:Exercise Might Benefit Some With Heart Failure 3
(Date:12/4/2009)OMAHA, Neb., Dec. 4 Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services. For nearly 15 years,
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received
Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred 4865 1Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred 4865 2Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred 4865 3The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 1The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 2The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 3The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 4The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 5Laureate Pharma Elects New Board Member 13606 1Laureate Pharma Elects New Board Member 13606 2
...nced Cancer Patients, ROCKVILLE, Md., April 9, 20...age pharmaceutical company developing,therapeutics...ases, today,announced that it has commenced a Phas...e inhibitor, ENMD-2076, in advanced cancer patient...ancer Center, will serve as,co-principal investiga...
...tivity of CR011-vcMMAE for ...results to be presented in June at 2008 ASCO ... Conn., April 9, 2008 CuraGen,Corporation (Nasdaq...any,focused on oncology, announced today that it h...te (ADC), into Phase II for the treatment of patie...
Other Medicine Technology:EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 2EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 4CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: